Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5…

Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage biotechnology company developing next-generation ...